Clinical Trial

Genotype-Guided Abbreviated DAPT Versus Un-Guided De-escalation Therapy in Patients With ACS and HBR

Study acronym: GUIDE-HBR
Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The aim of this study is to assess the safety and efficacy of the CYP2C19 genotype-guided abbreviated dual antiplatelet therapy (DAPT) strategy versus the un-guided stepwise intensity de-escalation of DAPT strategy in patients with acute coronary syndrome (ACS) and high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-01-01.
Trial Details
NCT Number NCT06763744
Lead Sponsor Samsung Medical Center
Conditions Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI), High Bleeding Risk
Enrollment 3,000 participants
Start Date 2025-06-01
Primary Completion 2029-07-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-05-18